Overview
Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in December 2008 on request of the sponsor.
On, 30 May 2001 orphan designation (EU/3/01/041) was granted by the European Commission to Bayer AG, Germany, recombinant human alpha-1 antitrypsin for the treatment of emphysema secondary to congenital alpha-1 antitrypsin deficiency.
The sponsorship was transferred to Talecris Biotherapeutics GmbH, Germany in March 2007.
Key facts
Active substance |
Recombinant human alpha-1 antitrypsin
|
Intended use |
Treatment of emphysema secondary to congenital alpha-1 antitrypsin deficiency
|
Orphan designation status |
Withdrawn
|
EU designation number |
EU/3/01/041
|
Date of designation |
30/05/2001
|
Sponsor |
Talecris Biotherapeutics GmbH
Lyoner Str. 15 D-60528 Frankfurt am Main Germany Telephone: +49 69 66 05 93 401 Telefax: +49 69 66 05 93 110 E-mail: wolfgang.schulten@talecris.com |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: